Evaluation and testing run through the whole development cycle: from BLI affinity and flow cytometry binding to multi-dimensional characterization and in vitro / in vivo efficacy, four services deliver accurate, reproducible, traceable data on standardized SOPs and advanced instrumentation.
Accurate, reliable in vitro efficacy evaluation is the foundation on which candidates are screened and optimised. SanjingBio's systematic platform reads functional activity at the cell level quickly and precisely, keyed to each target's mechanism, giving the early evidence that later development depends on.
In vivo efficacy screening is the pivotal preclinical step for antibodies, ADCs and other biologics, and it determines how truthfully a candidate's therapeutic potential is predicted. We assess tumour control and preliminary safety in standardised tumour-bearing models, providing the core evidence for advancing a candidate.
Cell and animal disease models are established to assess a candidate's biological activity, pharmacokinetics and therapeutic effect in full.
Mesothelin, long underestimated, has moved from the lab to the clinical frontier across CAR-T, ADCs and bispecifics. With our cellular EC50 and internalisation data.
May 27, 2026
Both formats drop parts of the native immunoglobulin. We compare structure, solubility, stability, size and production cost, then their therapeutic use.
Jul 15, 2026
Heavy-chain-only antibodies, found in camelids and cartilaginous fish in the 1990s, lose the CH1 domain and pair no light chain — leaving a single variable domain of roughly 15 kDa, nanometre-scale.
Jun 10, 2026
Every report ships with raw data and QC records. We align on the scientific question before designing the study, share key milestones live during execution, and tie conclusions to your development decisions.
Share the intended application and what you already have in hand. A scientist — not a sales rep — will scope feasibility, suggest the right route and send a quote, usually within one business day.
